Edition:
United States

People: Pfizer Inc (PFE)

PFE on New York Consolidated

33.64USD
21 Apr 2017
Change (% chg)

$-0.10 (-0.30%)
Prev Close
$33.74
Open
$33.64
Day's High
$33.73
Day's Low
$33.47
Volume
24,243,076
Avg. Vol
23,786,041
52-wk High
$37.39
52-wk Low
$29.83

Dolsten, Mikael 

Dr. Mikael Dolsten, M.D., Ph.D., is President - Worldwide Research and Development of the Company. He was Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until May 2010. He was Senior Vice President of Wyeth and President, Wyeth Research from June 2008 until October 2009. He was a Private Equity Partner at Orbimed Advisors, LLC from January 2008 until June 2008. Director of Karyopharm Therapeutics Inc. Chairman of the Translational Advisory Board of Apple Tree Partners.

Basic Compensation

Total Annual Compensation, USD 2,977,500
Restricted Stock Awards, USD 1,144,490
Long-Term Incentive Plans, USD --
All Other, USD 4,105,980
Fiscal Year Total, USD 8,227,970

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ian Read

17,321,500

Frank D'Amelio

7,694,350

Albert Bourla

8,870,440

Mikael Dolsten

8,227,970

John Young

7,395,740

Rady Johnson

--
As Of  30 Dec 2016